Amsterdam IADL Questionnaire

An up-to-date and psychometrically valid outcome measure, able to measure meaningful and early changes in everyday functioning.

As of January 2022, Brain Research Center has established a partnership with the Amsterdam UMC and will coordinate commercial licensing of the Amsterdam IADL Questionnaire. The Amsterdam IADL Questionnaire was developed in 2011, with the aim to improve the measurement of everyday functioning in people with (early) dementia, using innovative measurement techniques. The questionnaire has been extensively validated and used as an outcome measure in clinical trials.

Amsterdam IADL facts and figures




Trials have chosen the questionnaire, thus far


Validation studies

Amsterdam IADL Questionnaire in a nutshell

Measuring problems in Instrumental Activities of Daily Living (IADL) in early dementia.

Target population:
Community-dwelling population, memory clinic population, people at risk for dementia

Completed independently by study partner (e.g., spouse, child) or administered by a rater. Digital or paper-pencil.

10-15 minutes

Assessment burden:
Study partners perceived the questionnaire easy to complete, with clear questions and important content.


Instrumental activities of daily living (IADL) are vulnerable to the early effects of cognitive decline. For this reason, IADL is an important outcome measure for clinical (drug) trials, as acknowledged by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA).

The Amsterdam IADL Questionnaire was developed in 2012 and its content was carefully selected by relevant stakeholder to ensure content validity. One of the strengths of the Amsterdam IADL Questionnaire, compared to other (older) IADL questionnaires, is that items are included to cover nowadays everyday technology, as well as items applicable to a younger (<65 years) population.

Since the development in 2012, the questionnaire has been extensively validated in over 10 validation studies. In 2017, the short version was developed by extracting the 30 most frequently endorsed, relevant and informative activities from the original version while maintaining the psychometric qualities of the original version.

Findings validation studies Amsterdam IADL Questionnaire:

Excellent content validity

The content of the Amsterdam IADL Questionnaire was developed in collaboration with experts, patients, and caregivers.


Shows a high test-retest reliability.

Good construct validity

Amsterdam IADL Questionnaire scores are related to cognition and Alzheimer’s Disease biomarkers (gray matter atrophy and amyloid load)


Decline in IADL can already be detected in pre-dementia stages and is related to cognitive decline.

Clinically meaningful decline

Informal caregivers and clinicians determined the smallest amount of change (decline/improvement) that has an important effect on daily life.

Cross-cultural value

The Amsterdam IADL Questionnaire has been translated and cross-culturally adapted in many languages and therefore scores can be reliably compared between countries

Target population

The Amsterdam IADL Questionnaire was originally developed to capture IADL problems in (early) dementia.

  • The questionnaire can be used in clinical trials including at-risk populations for dementia as well as populations with mild to moderate dementia.
  • The questionnaire is most suitable for community dwelling populations but is also suitable for institutionalized subjects.
  • The questionnaire was originally developed to be completed by a study partner. While study partner report is advised for populations with moderate to severe dementia, a self-report version is available for pre-clinical or at-risk populations. This self-report version was recently developed and validated in a cognitively normal volunteer population.

While the Amsterdam IADL Questionnaire is originally developed for use in dementia, the questionnaire is suitable for other neurodegenerative diseases as well. The questionnaire is validated for use in brain tumor patients and an adapted version for patients with Multiple Sclerosis is currently being developed.


The Amsterdam IADL Questionnaire is originally developed in Dutch for the Netherlands, and English for the US as the second source language. The questionnaire has been translated into many languages, see the list below. A new translation can be requested, and takes around 12 weeks to become available. Brain Research Center has a preferred translation vendor, if another vendor is preferred, Brain Research Center must give explicit permission.

  • Arabic
  • Bulgarian
  • Catalan
  • Croatian
  • Czech
  • Danish
  • Dutch (NL, BE)
  • English (AU, CA, GB, US, HK, NZ)
  • Finnish
  • French (BE, CA, FR, CH)
  • German (DE, CH)
  • Greek
  • Hebrew
  • Hungarian
  • Icelandic
  • Italian (IT, CH)
  • Japanese
  • Korean
  • Mandarin (TW, CN, HK)
  • Norwegian
  • Polish
  • Portuguese (PT)
  • Romanian
  • Russian
  • Spanish (ES, US, AR)
  • Swedish (SE, FI)
  • Slovenian
  • Turkish (TR)



  • S.A. Sikkes, E.S. de Lange-de Klerk, Y.A. Pijnenburg, F. Gillissen, R. Romkes, D.L. Knol, et al.A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement. 8: 2012; 536– 54
  • S.A. Sikkes, D.L. Knol, Y.A. Pijnenburg, E.S. de Lange-de Klerk, B.M. Uitdehaag, P.Scheltens. Validation of the Amsterdam IADL Questionnaire(c), a new tool to measure instrumental activities of daily living in dementia. Neuroepidemiology. 41: 2013; 35– 4
  • Sikkes SAM, Pijnenburg YAL, Knol DL, de Lange-de Klerk ESM, Scheltens P, Uitdehaag BMJ. Assessment of instrumental activities of daily living in dementia: diagnostic value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. J Geriatr Psychiatry Neurol. 2013; 26(4): 244- 250.
  • Koster N, Knol DL, Uitdehaag BMJ, Scheltens P, Sikkes SAM. The sensitivity to change over time of the Amsterdam IADL Questionnaire((c)). Alzheimers Dement. 2015; 11(10): 1231- 124
  • Jutten RJ, Peeters CFW, Leijdesdorff SMJ, et al. Detecting functional decline from normal aging to dementia: development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement. 2017; 8: 26- 35.
  • Dubbelman MA, Verrijp M, Facal D, Sánchez-Benavides G, Brown LJE, van der Flier WM, Jokinen H, Lee A, Leroi I, Lojo-Seoane C, Milošević V, Molinuevo JL, Pereiro Rozas AX, Ritchie C, Salloway S, Stringer G, Zygouris S, Dubois B, Epelbaum S, Scheltens P, Sikkes SAM. The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. Alzheimers Dement (Amst). 2020 May 13;12(1):e12021.
  • Verrijp M, Dubbelman MA, Visser LNC, Jutten RJ, Nijhuis EW, Zwan MD, van Hout HPJ, Scheltens P, van der Flier WM, Sikkes SAM. Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report. Front Aging Neurosci. 2022;13:761932
  • Dubbelman MA, Terwee CB, Verrijp M, Visser LNC, Scheltens P, Sikkes SAM. Giving meaning to the scores of the Amsterdam instrumental activities of daily living questionnaire: a qualitative study. Health Qual Life Outcomes. 2022 Mar 24;20(1):4

Watch the Amsterdam IADL webinar

Want to hear what our experts have to say about the Amsterdam IADL questionnaire? Then request access to the webinar: Measuring and tracking everyday functioning in AD clinical trials with the A-IADL Questionnaire via the button below.

Contact us

If you are interested in using the Amsterdam IADL Questionnaire in your upcoming clinical trial, please email us via or click on the button below.


Director Business Development

Isadora Lopes Alves

Director Business Development

Isadora Lopes Alves is the Director Business Development, overseeing the acquisition, contracting and set-up of clinical trials. She is the first point of contact for potential clients wanting to work with Brain Research Center.
Director and neurologist

Niels Prins

Director and neurologist

Dr. Niels Prins is the director of Brain Research Center. He and his colleagues are committed to Alzheimer's disease and other brain diseases because he knows that clinical drug research can make a difference.
Operational director

Ad Hoeks

Operational director

Ad Hoeks is responsible for the overall operations of Brain Research Center.